More recently, a single arm, open-label trial phase II study in recurrent or persistent endometrial carcinoma patients reported that anti-tumor activity of 40 mg GDC-0980 daily was limited by tolerability, especially in diabetic patients, and patients with mutations of PI3K pathway may benefit more from GDC-0980 [91]. The gene discussed is PIK3CG; the disease is neoplasm.